Aktuellt
SENASTE
Redeye returns with a follow-up note to Genovis’ Q4’21 report. We are encouraged to see that Genovis is returning with higher growth and believe that the company has strong growth prospects in 2022 and onwards. We continue to see Genovis as a compelling investment and the share is one of Redeye’s Life Science Top Picks for 2022.
LÄS MER
